Pfizer Limited (PFIZER) - Total Assets
Based on the latest financial reports, Pfizer Limited (PFIZER) holds total assets worth Rs49.22 Billion INR (≈ $532.28 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Pfizer Limited reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Pfizer Limited - Total Assets Trend (2005–2026)
This chart illustrates how Pfizer Limited's total assets have evolved over time, based on quarterly financial data. Explore Pfizer Limited strategic investment ratio to see how much of total assets are deployed in long-term investments.
Pfizer Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Pfizer Limited's total assets of Rs49.22 Billion consist of 77.3% current assets and 22.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 63.2% |
| Accounts Receivable | Rs1.82 Billion | 3.7% |
| Inventory | Rs4.73 Billion | 9.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs143.50 Million | 0.3% |
| Goodwill | Rs5.27 Billion | 10.7% |
Asset Composition Trend (2005–2026)
This chart illustrates how Pfizer Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Pfizer Limited.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pfizer Limited's current assets represent 77.3% of total assets in 2026, an increase from 72.8% in 2005.
- Cash Position: Cash and equivalents constituted 63.2% of total assets in 2026, up from 30.9% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 26.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 10.7% of total assets.
Pfizer Limited Competitors by Total Assets
Key competitors of Pfizer Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $207.62 Billion |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
Pfizer Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.06 | 6.17 | 2.49 |
| Quick Ratio | 5.31 | 5.33 | 1.91 |
| Cash Ratio | 0.00 | 4.92 | 0.00 |
| Working Capital | Rs31.76 Billion | Rs29.43 Billion | Rs11.50 Billion |
Pfizer Limited - Advanced Valuation Insights
This section examines the relationship between Pfizer Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.00 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | Rs49.22 Billion |
| Market Capitalization | $2.25 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Pfizer Limited's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Pfizer Limited's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Pfizer Limited (2005–2026)
The table below shows the annual total assets of Pfizer Limited from 2005 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs49.22 Billion ≈ $532.28 Million |
+0.22% |
| 2025-03-31 | Rs49.11 Billion ≈ $531.12 Million |
+16.14% |
| 2024-03-31 | Rs42.29 Billion ≈ $457.33 Million |
+5.70% |
| 2023-03-31 | Rs40.01 Billion ≈ $432.66 Million |
+2.57% |
| 2022-03-31 | Rs39.01 Billion ≈ $421.83 Million |
+19.43% |
| 2021-03-31 | Rs32.66 Billion ≈ $353.19 Million |
-25.87% |
| 2020-03-31 | Rs44.05 Billion ≈ $476.43 Million |
+11.81% |
| 2019-03-31 | Rs39.40 Billion ≈ $426.09 Million |
+6.78% |
| 2018-03-31 | Rs36.90 Billion ≈ $399.06 Million |
+12.82% |
| 2017-03-31 | Rs32.71 Billion ≈ $353.71 Million |
+12.25% |
| 2016-03-31 | Rs29.14 Billion ≈ $315.11 Million |
+11.57% |
| 2015-03-31 | Rs26.12 Billion ≈ $282.43 Million |
+182.53% |
| 2014-03-31 | Rs9.24 Billion ≈ $99.96 Million |
-55.12% |
| 2013-03-31 | Rs20.60 Billion ≈ $222.73 Million |
+30.64% |
| 2012-03-31 | Rs15.76 Billion ≈ $170.49 Million |
+13.72% |
| 2011-03-31 | Rs13.86 Billion ≈ $149.92 Million |
+15.20% |
| 2010-03-31 | Rs12.03 Billion ≈ $130.14 Million |
+9.63% |
| 2009-03-31 | Rs10.98 Billion ≈ $118.71 Million |
+26.53% |
| 2008-03-31 | Rs8.67 Billion ≈ $93.81 Million |
+34.18% |
| 2007-03-31 | Rs6.47 Billion ≈ $69.92 Million |
+12.23% |
| 2006-03-31 | Rs5.76 Billion ≈ $62.30 Million |
+10.32% |
| 2005-03-31 | Rs5.22 Billion ≈ $56.47 Million |
-- |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more